Darifenacin, the active ingredient in Xelena, is commonly used in adults for managing symptoms associated with Overactive Bladder (OAB) syndrome. This medication is applied in clinical settings to help with symptoms of urinary urgency, urinary frequency, and urge urinary incontinence. It is relevant for easing the persistent and distressing manifestations of OAB.

Therapeutic Support and Comfort

This medication is primarily relevant for easing the persistent and distressing manifestations of OAB, which are symptoms related to heightened physiological activity of the bladder muscle. The therapeutic goal is to increase the bladder's functional ability to hold urine, which directly contributes to improved comfort and stability.

Quick Fact: Relief for Urinary Urgency Used in situations involving symptoms that interfere with daily functioning, Xelena may assist with maintaining functional stability by reducing the sudden, compelling need to void.

The support provided by this medication helps patients cope more steadily with their chronic condition. This assistance with core OAB symptoms contributes to easing the overall symptom load and facilitates a more comfortable engagement in routine activities.

Official Population Eligibility for Xelena

The eligibility profile for Xelena (Darifenacin Hydrobromide) is defined by official regulatory criteria, focusing on age, organ function, and pre-existing medical conditions.

Approved Population:

• Use is established for adults (18 years of age and older). Geriatric patients do not require dosage adjustments based on age alone, as regulatory data indicates a comparable safety profile to younger adults.

Absolute Contraindications:

• Xelena is strictly contraindicated in individuals with a high risk of fluid retention, including urinary retention and gastric retention.
• The medicine is also prohibited for patients with uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis, toxic megacolon, or known hypersensitivity to the medication.

Use Restrictions and Limitations:

• Use is not recommended for pediatric patients (under 18 years of age) because safety and efficacy have not been formally established.
• The medicine is not recommended for patients with severe hepatic impairment (Child-Pugh Class C).
• Caution is required for patients with moderate hepatic impairment (Child-Pugh Class B), where the maximum daily intake is officially restricted.
• Use is generally not recommended during pregnancy or breastfeeding.

Interactions with other medicines and products

XENLETA's interaction profile is primarily defined by its effects on the cytochrome P450 (CYP3A) enzyme system and the P-glycoprotein (P-gp) efflux transporter.

Interacting Product Category	Regulatory Constraint	Interaction Mechanism/Basis
Sensitive CYP3A Substrates that prolong the QT interval	Contraindicated with XENLETA Tablets	Risk of increased plasma concentrations of the co-administered drug, potentially leading to QT prolongation (e.g., pimozide).
Strong or Moderate CYP3A Inhibitors or P-gp Inhibitors	Avoid XENLETA Tablets	May increase the plasma concentration of XENLETA, increasing the risk of adverse reactions.
Strong or Moderate CYP3A Inducers or P-gp Inducers	Avoid XENLETA unless benefit outweighs risk	May significantly decrease the exposure to XENLETA, potentially leading to reduced efficacy (treatment failure).

Concomitant use with midazolam and other sensitive CYP3A substrates requires monitoring for adverse reactions, as XENLETA is a CYP3A inhibitor and may raise the levels of co-administered sensitive substrates. This structure establishes clear avoidance rules for certain combinations, particularly those involving drugs with a known risk of QT prolongation, and management requirements for combinations that affect XENLETA's metabolic clearance.

Selective Blockade of Muscarinic M3 Receptors

Xelena works by acting as a competitive antagonist primarily on the M3 muscarinic receptor subtype, which are highly concentrated on the detrusor smooth muscle. By binding selectively to these receptors, the active ingredient, Darifenacin, blocks the action of the excitatory neurotransmitter Acetylcholine (ACh), thereby blocking the transmission of the excitatory signal for muscle contraction.

---

Interruption of the Cholinergic Contractile Cascade

This molecular blockade prevents the activation of the subsequent Gq-protein signaling cascade and inhibits the release of intracellular calcium ions (Ca^2+), the key step required for muscle shortening. This interruption results in sustained detrusor muscle relaxation, a physiological consequence that contributes to the reduction of spontaneous cellular activity within the bladder wall.

---

Modulation of Peripheral Smooth Muscle Tone

The sustained detrusor muscle relaxation modulates the excessive, involuntary contractile tone. This targeted modulation results in an increase of the bladder's functional capacity (volume) due to the reduced contractile response to stimuli.

How Xelena (Darifenacin Hydrobromide) is Used

Xelena is administered via the oral route as an extended-release tablet and is typically part of a long-term treatment plan. The medication is taken once daily (q.d.) and can be consumed with or without food. To ensure the controlled, gradual release of the active ingredient, the extended-release tablet must always be swallowed whole with water and must not be chewed, divided, or crushed.

Dosing and Administration Schedule

Administration begins with the lowest dose, and adjustments are made based on the individual's response, following a defined schedule.

Instruction	Guideline
Initial Daily Dose (Adults)	7.5 mg once daily
Maximum Daily Dose (Adults)	15 mg once daily
Dose Titration Schedule	Dose may be increased after a minimum of two weeks of treatment

Population-Specific Use

Specific usage constraints exist for certain patient groups to ensure proper administration. For patients with moderate hepatic impairment or those concurrently taking a potent CYP3A4 inhibitor, the daily dose must not exceed 7.5 mg. Use is generally not recommended for patients with severe hepatic impairment or for pediatric patients under 18 years of age, due to a lack of established data.

Handling Missed Doses

If a dose is missed, patients are to omit the missed dose and resume the regular once-daily schedule the following day. Patients must not attempt to double the dose to compensate for the omission.

Xelena: Recent Clinical Evidence

The following summary reflects findings reported in clinical trials and studies concerning the compound Xelena (darifenacin) for overactive bladder (OAB) symptoms.

---

Phase II and III Clinical Trials

• Initial Phase II trials evaluated whether the compound was associated with an improvement in symptom severity across a cohort of participants, with data indicating a numerical difference in scores, though the primary endpoint was not universally met for this stage of testing.
• Phase III trials were conducted in larger randomized controlled settings. The primary outcome measure in key trials was a change in validated scoring systems that track disease activity and symptom frequency. The mean difference between the active compound group and the placebo group was recorded for the primary outcomes.
• Research examined the long-term changes in bladder control and reported events over periods extending up to one year.

---

Reported Events

Side effects frequently reported in the trials included dry mouth, constipation, and headache. Other reported occurrences included nausea, dry eye, and blurred vision.

• These events were documented, and many were recorded as transient.
• Long-term data reports on reported events and occurrences of the compound, with no new significant signals reported during open-label extension studies.

---

Research Gaps

• Evidence remains limited regarding the compound’s use in pediatric populations, as definitive trials primarily enrolled adult participants.
• It is not yet clear whether the long-term effects on remission or symptom maintenance differ substantially from existing treatment options, as head-to-head trials against all alternatives have not been published.

Common questions about Xelena (FAQ)

Q: How long after starting Xelena do people typically notice an effect?

A: Pharmacokinetic studies indicate that a stable concentration of the medicine in the body is typically reached within the first week of dosing. Dose adjustments, if required, are recommended to occur after a minimum of two weeks of treatment, according to regulatory guidelines.

Q: Is Xelena safe to use for a long period of time?

A: Clinical trials, including long-term studies that extended up to one year, examined the safety profile of Xelena. Official documentation states that the side effect profile seen during the long-term phase was consistent with the initial studies, and no new safety signals of concern were detected over the extended period.

Q: What's the difference between Xelena and the similar medicine I saw advertised?

A: Official pharmacological documents describe Xelena as a type of anticholinergic medication. The medicine is noted for its high selectivity for the M3 muscarinic receptor, which is an action intended to focus its effect primarily on the muscle of the bladder.

Q: Are there generic versions of Xelena available?

A: The active ingredient in Xelena, called darifenacin, is available in an extended-release tablet form, and generic versions of this medicine may be approved and available. You can check public databases like the FDA Orange Book for current status information.

Q: Is it common to feel tired when first taking Xelena?

A: According to the official product information based on clinical trials, somnolence (drowsiness) and asthenia (a feeling of unusual weakness or lack of energy) were reported as uncommon side effects. These effects were not among the most frequently observed reactions.

Q: Are there any known interactions between Xelena and common pain relievers?

A: Official product information focuses on potential interactions with medicines that affect the CYP450 enzyme system, which breaks down Xelena in the body. General non-prescription pain relievers (such as paracetamol or NSAIDs) are not specifically named in regulatory documents as requiring a dose change when taken with Xelena.

Q: Does Xelena affect contraception or birth control pills?

A: Studies have been conducted on the use of Xelena with combined oral contraceptives. The available official data does not indicate that Xelena alters the effectiveness of these combination oral contraceptives.

Q: Does Xelena interact with herbal supplements like St. John's wort?

A: Yes, official documentation advises caution regarding certain herbal supplements. Substances that are CYP3A4 enzyme inducers, such as St. John's wort (Hypericum perforatum), are expected to decrease the level of Xelena in the bloodstream.

Q: Is Xelena known to cause mood changes or depression?

A: Central Nervous System effects are described in regulatory sources. Post-marketing experience includes reports of altered mood, depressed mood, confusion, and hallucinations, which are associated with this class of medication.

Q: Can Xelena be taken at the same time as my other morning medicines?

A: Xelena is a once-daily medicine and can be taken at any time of day, with or without food. However, official labeling highlights that certain drug combinations (e.g., with potent enzyme inhibitors) have clear restrictions on the maximum dose of Xelena.

Q: What is the main class of drug that Xelena belongs to?

A: Xelena is a prescription medicine classified as an anticholinergic agent. It is more specifically defined as a selective antagonist of the M3 muscarinic receptor.

Q: What kind of monitoring or tests are needed while on Xelena?

A: Regulatory information indicates that if Xelena is used alongside certain other medicines, monitoring of the concentration of the co-administered medicine in the blood may be required. This is done when starting or stopping Xelena to ensure the other medicine remains at a safe level.

Q: Does Xelena have any known interactions with alcohol?

A: Official drug information advises that taking Xelena with alcohol may increase the risk of certain side effects. This combination may increase the likelihood of experiencing effects like dizziness or feeling faint.

Q: Are there different strengths of Xelena available?

A: The official Prescribing Information confirms that Xelena extended-release tablets are available in two product strengths: 7.5 mg and 15 mg.

Q: Does Xelena interact with blood pressure medication?

A: Official drug interaction summaries focus on enzyme systems (CYP450). Caution is advised for medicines that are metabolized by the CYP2D6 enzyme and have a narrow therapeutic window, which may include some cardiovascular and blood pressure medications. Official documentation does not provide a general statement regarding all blood pressure medicines.

Q: Is Xelena available over the counter in some countries?

A: Across major regulatory regions, including the United States, Europe, and Australia, Xelena is classified as a prescription-only medicine (Rx-only). It is not available for purchase over the counter.

Q: Does Xelena have a black box warning in the US?

A: The review of the US Prescribing Information for Xelena (darifenacin) confirms that the medicine does not contain an FDA-mandated Boxed Warning, which is commonly known as a Black Box Warning.

Q: Can Xelena affect my ability to drive or operate machinery?

A: Regulatory sources advise that Xelena may cause side effects such as blurred vision, dizziness, or drowsiness (somnolence). Official safety information recommends not driving or operating complex machinery until a person understands how the medicine affects them.

Q: What kind of benefits did patients in the clinical trials report from Xelena?

A: Clinical trials reported that patients experienced measurable differences in symptoms when compared to placebo. These differences included a reduction in the frequency of incontinence episodes, a decrease in the number of voids per day, and a decrease in the number and severity of urgency episodes.

Q: How does Xelena compare to other common treatments for the same condition?

A: Official pharmacological descriptions classify Xelena as a selective M3 muscarinic antagonist. This specific action is recognized as the characteristic that differentiates it from other medicines in the broader anticholinergic class.

Q: Does Xelena interfere with sleep?

A: Insomnia (difficulty sleeping) was reported as an uncommon side effect in the clinical trials that tested Xelena, according to official adverse reaction documents.

Q: What is the general success rate reported for Xelena in trials?

A: Clinical trial results documented the percentage of patients who achieved complete dryness or a significant reduction in incontinence episodes. Official data indicated numerical improvements in these primary outcomes when comparing the group taking Xelena to the group taking a placebo.

Q: Are skin rashes a common or serious side effect of Xelena?

A: Official adverse reaction documents list skin rash, pruritus (itching), and dry skin as uncommon side effects. Serious but rare events, such as angioedema (severe swelling) and erythema multiforme, are also documented in official labeling.

Q: Do studies suggest Xelena can be used during pregnancy?

A: Studies conducted in animals showed an increased incidence of fetal damage. The clinical significance of these findings in humans is considered uncertain. Official labeling advises that Xelena is generally not recommended during pregnancy, with use only considered if the potential benefit is determined to outweigh the potential risk.

The official storage requirements for Xelena (darifenacin hydrobromide) extended-release tablets are defined to maintain product stability.

Storage Conditions

Requirement	Rule
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Brief excursions up to 30 C (86 F) are permitted.
Protection	Keep away from heat, moisture, freezing, and direct light. Store in a closed container.
Child Safety	Keep out of the reach of children.

Disposal Instructions

Dispose of unused or expired Xelena using an authorized drug take-back program as the preferred method. If no take-back option is available and the medicine is not on the FDA flush list, mix the tablets with an undesirable substance (like coffee grounds or dirt), place the mixture in a sealed bag or container, and discard it in the household trash.